KDR and acute myeloid leukemia: Regarding azaindole-based scaffolds (6 and 7), each acted as a tris kinase inhibitor (FLT-3, GSK-3β, VEGFR-2, and CSF1R, KIT) and FLT3-ITD, respectively), so, they could combat against both on and off-target mutations related to FLT3 AML harboring cells.